Meta-analysis of ursodeoxycholic acid and S-adenosylmethionine for improving the outcomes of intrahepatic cholestasis of pregnancy

• Published in: Zhonghua gan zang bing za zhi Vol. 22; no. 4; p. 299
• Main Authors: Zhou, Fan, Gao, Bingxin, Wang, Xiaodong, Li, Jing
• Format: Journal Article
• Language: Chinese
• Published: China 01.04.2014
• Subjects: Cholestasis, Intrahepatic - drug therapy; Drug Therapy, Combination; Female; Humans; Pregnancy; Pregnancy Complications - drug therapy; Pregnancy Outcome; Randomized Controlled Trials as Topic; S-Adenosylmethionine - administration & dosage; S-Adenosylmethionine - adverse effects; S-Adenosylmethionine - therapeutic use; Ursodeoxycholic Acid - administration & dosage; Ursodeoxycholic Acid - adverse effects; Ursodeoxycholic Acid - therapeutic use
• ISSN: 1007-3418
• DOI: 10.3760/cma.j.issn.1007-3418.2014.04.013

To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) that have assessed the effect and safety of ursodeoxycholic acid (UDCA), S-adenosylmethionine (SAMe) and UDCA-SAMe combination therapies for intrahepatic cholestasis of pregnancy (ICP). Using searching protocols and assessment methods recommended by the Cochrane Collaboration to reduce bias in systematic reviews, the databases of Medline, EMBASE, Cochrane Central Register of Controlled Trials (CCRT), China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature (CBM) and Wanfang China Online Journals were searched to identify relevant RCTs published from database inception to December 2011. Ten RCTs (of 727 pregnant women) were included in the study and represented a low risk for bias. Compared to the patients who received UDCA monotherapy, those who received UDCA-SAMe combination therapy had significantly lower rates of Cesarean section (odds ratio (OR) =0.45, 95% confidence interval (CI):0.24-0.86), prete